United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) today announced positive results from its phase 1 study of miroliverELAP®, an external liver assist product, in patients with acute forms of liver failure, acute-on-chronic liver failure, and severe acute alcoholic hepatitis, collectively called acute liver failure (ALF).2 Developed by Miromatrix Medical Inc., a wholly owned subsidiary of United Therapeutics, miroliverELAP consists.

Business Wire • Jan 26, 2026

United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors

SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Kevin J. Tracey, M.D., to its Board on January 21, 2026. Dr. Tracey is President, CEO, and the Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research. He is a Professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medic.

Business Wire • Jan 22, 2026

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jan 16, 2026

Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Jan 15, 2026

United Therapeutics Corporation (UTHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

United Therapeutics Corporation (UTHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

Top stock-market newsletter editors share gems from their ‘buy' list.

Market Watch • Jan 12, 2026

UTHR or MDGL: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Madrigal (MDGL). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Jan 8, 2026

UTHR vs. ZTS: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Drugs sector might want to consider either United Therapeutics (UTHR) or Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Jan 7, 2026

United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference

SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will present a company overview and update on Monday, January 12, 2026, from 1:30 to 2:10 p.m. PST, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An ar.

Business Wire • Jan 5, 2026

Here's Why United Therapeutics (UTHR) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Dec 31, 2025